VIR - Vir Biotechnology, Inc.

10.35
-0.320   -3.092%

Share volume: 1,227,260
Last Updated: 04-23-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$10.67
-0.32
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 23%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.67%
1 Month
20.77%
3 Months
38.93%
6 Months
73.08%
1 Year
64.55%
2 Year
12.50%
Key data
Stock price
$10.35
P/E Ratio 
0.00
DAY RANGE
$10.27 - $10.80
EPS 
-$3.13
52 WEEK RANGE
$4.16 - $11.66
52 WEEK CHANGE
$69.12
MARKET CAP 
838.924 M
YIELD 
N/A
SHARES OUTSTANDING 
139.517 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$2,022,936
AVERAGE 30 VOLUME 
$1,907,617
Company detail
CEO: George A. Scangos
Region: US
Website: vir.bio
Employees: 580
IPO year: 2019
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs, for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health.

Recent news